ArticleThe Journal of general virology2020
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
Article in The Journal of general virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Development-A Systematic Review.Viruses · 2022Pooled it
- Pooled it
- Integrated Laboratory Evaluation of Rift Valley Fever Virus Antibodies Using the Competitive ELISA and Virus Neutralization Test.Pathogens (Basel, Switzerland) · 2026Article
- Article
- HSV-1 virions and related particles: biogenesis and implications in the infection.Journal of virology · 2025Review
- EfficientAntimicrobial agents and chemotherapy · 2025Article
- Efficacy of dispirotripiperazine PDSTP in a golden Syrian hamster model of SARS-CoV-2 infection.Frontiers in microbiology · 2025Article
- A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.Journal of virology · 2024Article
- No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model.PloS one · 2024Article
- Relevance of the Entry by Fusion at the Cytoplasmic Membrane vs. Fusion After Endocytosis in the HIV and SARS-Cov-2 Infections.Results and problems in cell differentiation · 2024Article
- Nanoisland SERS-Substrates for Specific Detection and Quantification of Influenza A Virus.Biosensors · 2023Article
- Generation of quality-controlled SARS-CoV-2 variant stocks.Nature protocols · 2023Review
- Article
- Isolation of ACE2-dependent and -independent sarbecoviruses from Chinese horseshoe bats.Journal of virology · 2023Article
- Targeting spike glycans to inhibit SARS-CoV2 viral entry.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A non-transmissible live attenuated SARS-CoV-2 vaccine.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Multiplex Lithographic SERS Aptasensor for Detection of Several Respiratory Viruses in One Pot.International journal of molecular sciences · 2023Article
- Systematic Exploration of SARS-CoV-2 Adaptation to Vero E6, Vero E6/TMPRSS2, and Calu-3 Cells.Genome biology and evolution · 2023Article
- Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy.Acta crystallographica. Section D, Structural biology · 2023Article
- Viral infectivity in paediatric SARS-CoV-2 clinical samples does not vary by age.Access microbiology · 2023Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged at the end of 2019 and by mid-June 2020 the virus had spread to at least 215 countries, caused more than 8 000 000 confirmed infections and over 450 000 deaths, and overwhelmed healthcare systems worldwide. Like severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 and caused a similar disease, SARS-CoV-2 is a betacoronavirus. Both viruses use human angiotensin-converting enzyme 2 (hACE2) as a receptor to enter cells. However, the SARS-CoV-2 spike (S) glycoprotein has a novel insertion that generates a putative furin cleavage signal and this has been postulated to expand the host range. Two low-passage (P) strains of SARS-CoV-2 (Wash1 : P4 and Munich : P1) were cultured twice in Vero E6 cells and characterized virologically. Sanger and MinION sequencing demonstrated significant deletions in the furin cleavage signal of Wash1 : P6 and minor variants in the Munich : P3 strain. Cleavage of the S glycoprotein in SARS-CoV-2-infected Vero E6 cell lysates was inefficient even when an intact furin cleavage signal was present. Indirect immunofluorescence demonstrated that the S glycoprotein reached the cell surface. Since the S protein is a major antigenic target for the development of neutralizing antibodies, we investigated the development of neutralizing antibody titres in serial serum samples obtained from COVID-19 human patients. These were comparable regardless of the presence of an intact or deleted furin cleavage signal. These studies illustrate the need to characterize virus stocks meticulously prior to performing either
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.